The United Kingdom and the United States have agreed to a landmark trade agreement that will keep no tariffs on British drug shipments being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to raise expenditure on medicines through the National Health Service (NHS). This pledge secures that tariffs on these vital goods will be held at nothing for a timeframe of 36 months.
This agreement follows earlier warnings to significantly raise duties on branded drug products, with increases discussed as high as double the cost.
"This deal with the United Kingdom bolsters the global environment for new treatments and brings much-needed equity to U.S.–U.K. drug exports," an announcement declared.
Trade Significance
Pharmaceuticals constitute one of the the United Kingdom's largest export categories to the America, which is clearly the biggest destination for major UK drugmakers.
Export figures indicate that in the 12 months prior to the third quarter, the UK exported medicines valued at £11.1bn to the US. This amount represented 17.4% of all goods exports in that timeframe.
"This guarantee safeguards jobs, increases investment and facilitates the UK to become a worldwide center for medical research," a government official remarked.
Key UK Commitments
The agreement involves several notable pledges from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to double total health service expenditure on drugs from 0.3% of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount drug companies must return to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds exceeded 20%.
Industry Background
This agreement comes amid a long-running tension between the sector and the ministers over medicine costs and approval rates.
These tensions were exacerbated by assertions that US patients were charged a premium for the same drugs than consumers in the UK and Europe.
In recent months, several significant drug company projects in the UK have been halted or abandoned, while multi-billion-dollar investments have been announced toward American operations.
The Science Minister acknowledged that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a proportion of its resources over the previous ten-year period.
